Asdar Group - Renegotiation of Agreement With ACGT Corporation.Business Editors VANCOUVER, British Columbia--(BUSINESS WIRE)--March 27, 2002 Asdar Group (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : XBET) reports that it will be conducting further discussions with ACGT ACGT Alliance for Cancer Gene Therapy ACGT Advisory Committee on Genetic Testing ACGT Advanced Center for Genome Technology ACGT Arts Commission of Greater Toledo ACGT A Comparative Genomics Tool (comparison viewer and analyzer) Corporation to renegotiate re·ne·go·ti·ate tr.v. re·ne·go·ti·at·ed, re·ne·go·ti·at·ing, re·ne·go·ti·ates 1. To negotiate anew. 2. To revise the terms of (a contract) so as to limit or regain excess profits gained by the contractor. the terms and conditions of its initial agreement with the Toronto based Biotechnology Company. To avoid possible conflicts of interest, the Company has accepted the resignation of Dr. Hai Shiene Chen as a Director prior to its new discussions with ACGT Corporation. Asdar Group has also initiated discussions to acquire an interest in other companies working in the biotech field. In conjunction with this new direction for the Company, it is proceeding with the previously announced name change to "Precise Life Sciences Ltd." /s/ Conrado Beckerman Conrado Beckerman, President Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995; The statements contained herein which are not historical fact are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays in testing and evaluation of products and other risks detailed from time to time in Asdar's filings with the Securities & Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion